Axis Capital (AXS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.
Axis Capital (AXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
| Insurance Industry | Financials Sector | Vincent C. Tizzio CEO | XDUS Exchange | BMG0692U1099 ISIN |
| BM Country | 2,033 Employees | 30 Jun 2026 Last Dividend | 12 Sep 2014 Last Split | 1 Jul 2003 IPO Date |
AXIS Capital Holdings Limited is a global provider of specialty insurance and reinsurance products, offering a comprehensive portfolio of services to a diverse range of clients. Established in 2001 and headquartered in Pembroke, Bermuda, AXIS operates through two main segments: Insurance and Reinsurance. The company has a broad international presence, serving clients not only in Bermuda and the United States but also in various other countries around the world. Through its insurance and reinsurance segments, AXIS is dedicated to providing tailored solutions to meet the complex needs of its clients, spanning from commercial enterprises and financial institutions to not-for-profit organizations and professional service providers.
AXIS Capital Holdings Limited offers a wide range of specialty insurance and reinsurance products, categorized under its Insurance and Reinsurance segments: